🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany ◆ Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact ◆
Clinical Trials in France / NCT07733193
Starting soon Phase 3

Impact of Prophylactic Bone Radiation Therapy in Patients With Bone Metastases.

NCT07733193 · tracked via the Priya Life Science France tracker
Phase
Phase 3
Started
2026-09-01
Last updated
2026-07-29

Condition(s) studied

Bone Metastases

Investigational drug(s) / intervention(s)

prophylactic radiationstandard of care

prophylactic radiation: Patients will undergo propthylactic radiation on bone metastases

standard of care: Patients will have systemic treatment on the standard of care

Study summary

Radiation therapy is a common treatment for painful bone metastases, proving effective in 1 to 2/3 of cases after 1 to 10 sessions, with stereotactic body radiation therapy (SBRT) likely offering superior results.

Radiation therapy is also used to prevent bone events, although its use is not standardized; the decision to administer it is made by clinicians or through multidisciplinary team (MDT) discussions.

Recently, it has been shown that preventive radiation therapy can reduce the risk of skeletal-related events (SREs) in patients at high risk for bone events.

The objective is to compare active surveillance with preventive radiation therapy in patients at intermediate risk for bone events.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Men or women, 18 years of age or older * Patients with solid cancer and bone metastases * Patients with bone lesions considered to be at intermediate risk for skeletal-related events (SINS score between 7 and 12, Mirels 8) or patients with lesions accompanied by Grade 1 epiduritis (Bilsky) * Enrolled in or covered by a social insurance program * Patients with an estimated life expectancy of more than 6 months Exclusion Criteria: * Hematologic disease * Patients with a lesion at high risk for skeletal-related events (SINS score of 13 or higher, MIRELS score of 9 or higher, or a multidisciplinary team (MDT) recommendation that surgery is necessary) * Patients with pain secondary to bone lesions requiring radiation therapy * Contraindication to radiation therapy due to a history of radiation therapy at the same site or a condition contraindicating radiation therapy * Pregnant or breastfeeding women * Contraindication to MRI in cases of spinal lesions; contrast-enhanced CT scan * Patients unable to understand the study for any reason or to comply with the trial requirements (language, psychological, geographic issues, etc.) * Patients under legal guardianship or conservatorship * Patients classified as WHO 3 or 4

Primary outcome measure(s)

Trial sites (2)

FacilityCityRegionStatus
Institut de Cancérologie de Lorraine Nancy France
Centre Henri Becquerel Rouen France

More Centre Henri Becquerel trials in France

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07733193 on ClinicalTrials.gov ↗ ← All trials in France